INmune Bio Demonstrates Significant Improvement in Alzheimer’s Disease Patients with Weekly XPro™ Treatment

Immunology company, INmune Bio, Inc. (Nasdaq: INMB) has demonstrated significant improvements in electroencephalography (EEG), a biomarker of brain function, in patients with moderate to severe Alzheimer’s Disease (AD) treated with XPro™ for four weeks.  XPro™ works by reducing neuroinflammation to stop or slow the progression of cognitive and psychiatric symptoms of AD.

CJ Barnum, PhD, VP of Neuroscience at INmune Bio, said, “Functional benefits are the true benchmark of a drug’s biological efficacy, and these promising findings are part of a larger narrative that’s still unfolding. We are committed to extensive research, drawing from our Phase 2 placebo-controlled trial to substantiate these findings.”

Highlights 

INmune’s pilot study enrolled seven patients with moderate to severe AD and evaluated the utility of EEG as a functional biomarker of target engagement in evaluating the effects of XPro™.

Patients who received weekly XPro™ treatment for four weeks had a statistically significant increase in Alpha wave frequency and power. Reduced Alpha power is linked with cognitive decline and the progression of Alzheimer’s Disease.

The study’s positive results reinforce the findings of the company’s Phase 1 study that showed XPro™ treatment reduced biomarkers of inflammation and improved biomarkers of neurodegeneration, synaptic function and improved brain microstructure and promoted remyelination.

INmune is assessing the extent to which these biomarker changes impact cognition in patients in its ongoing randomized, placebo-controlled Phase 2 trial. 

About INmune Bio, Inc.

INmune Bio, Inc. is a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. INmune Bio has two product platforms that are both in clinical trials: The Dominant-Negative Tumor Necrosis Factor (DN-TNF) product platform utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and a mechanistic driver of many diseases. XPRO, the first of several DN-TNF products, is in clinical trials to determine if it can treat patients with Mild Alzheimer’s disease. Additional therapeutic indications including d treatment-resistant depression and oncology will be pursued when resources allow. The Natural Killer Cell Priming Platform includes INKmune™, a therapy developed to prime a patient’s NK cells to treat patients with cancer. INKmune uses a precision medicine approach for the treatment of a wide variety of hematologic and solid tumor malignancies. The INKmune trial is enrolling patients into a US Phase I/II trial in men with metastatic castrate resistant prostate cancer. To learn more, please visit www.inmunebio.com.